WLF Decision Could Discourage Publishing Of Studies To Avoid Piggybacking
Executive Summary
Manufacturers may be deterred from publishing their studies in order to avoid having the trials used by competitors following the July 28 federal court decision removing the prohibition on distributing off-label studies sponsored by competitors.
You may also be interested in...
FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.
FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer
FDA will not be permitted to object to off-label reprints as "false and misleading" when the agency finds technical problems with an article, attorney Daniel Troy (Wiley, Rein & Fielding) asserted at an Aug. 18 Washington Legal Foundation forum on the impact of the recent WLF v. Henney off-label information dissemination ruling.
FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer
FDA will not be permitted to object to off-label reprints as "false and misleading" when the agency finds technical problems with an article, attorney Daniel Troy (Wiley, Rein & Fielding) asserted at an Aug. 18 Washington Legal Foundation forum on the impact of the recent WLF v. Henney off-label information dissemination ruling.